Viewing nowBriva 25 mg (Brivaracetam)
Brivaracetam 25mg
Tablet · Prescription medication
Hanin Pharmaceutical Co., Ltd.

MFDS item code 202502492 · Approved 2025.09.19
Adjunctive treatment of partial-onset seizures in patients with epilepsy aged 16 years and older
This medication is used as an adjunctive treatment for the management of partial seizures occurring in patients with epilepsy aged 16 years and older, regardless of whether they have secondary generalized seizures or not. It is used to more effectively control symptoms alongside the primary therapy, helping to reduce the frequency and intensity of seizures. Being an adjunctive therapy, it will be administered along with other antiepileptic drugs. It contributes to overall seizure management, helping patients to achieve a more stable daily life. For these reasons, it is used as adjunctive therapy in the treatment of partial seizures.
This medicine is taken twice daily. The recommended initial dose is 25mg or 50mg per dose, based on the healthcare professional's assessment of potential adverse effects relative to seizure reduction. Based on clinical response and tolerability, the dose may be increased or decreased from 50mg per day [25mg per dose, twice daily] to 200mg per day [100mg per dose, twice daily]. Swallow this film-coated tablet whole with water. It may be taken with or without food. If you miss a dose If you miss one or more doses, take one dose as soon as you remember, and then take the next dose at the next scheduled morning or evening time. Discontinuation If you wish to stop taking this medicine, gradually reduce the dose by 50mg per day at 1-week intervals. After taking 50mg per day for 1 week, a dose of 20mg per day is recommended for the final week (see section 2. Warnings). Older adults (65 years and older) No dosage adjustment is required in older adults. Clinical experience in patients aged 65 years or older is limited. Renal impairment No dosage adjustment is required in patients with renal impairment. This medicine is not recommended for patients with end-stage renal impairment who are receiving hemodialysis. Hepatic impairment Exposure to this medicine is increased in patients with hepatic impairment. The recommended initial dose for patients with hepatic impairment is 50mg per day [25mg per dose, twice daily], and the recommended maximum dose is 150mg per day [75mg per dose, twice daily].
This medication is used for the treatment of epilepsy and may slightly increase the risk of mental health issues such as suicidal thoughts or behaviors, thus symptoms should be monitored closely during treatment. Also, central nervous system-related side effects such as drowsiness, fatigue, and dizziness may commonly occur, so caution is advised when engaging in activities that require focus, such as driving or operating machinery. Discontinuing this medication abruptly may lead to more frequent seizures, so the dosage should be gradually reduced in accordance with the doctor's instructions. If allergic reactions to this medication or similar medications occur, it should not be taken, and individuals with specific genetic issues such as lactose intolerance should also avoid it. Patients with reduced liver function may need dosage adjustments, so they should consult their doctor. This medication can cause skin rashes or severe skin reactions (like Stevens-Johnson syndrome), so patients should notify healthcare professionals immediately if any unusual skin symptoms occur. Taking this medication with alcohol may impair mental motor function and attention, so it is advisable to avoid alcohol. Because it can interact with other medications, it is essential to inform the doctor or pharmacist, especially if taking other antiepileptic drugs, certain antibiotics, or oral contraceptives. Women who are pregnant or planning to become pregnant need careful evaluation regarding the use of this medication, and breastfeeding mothers should consult specialists since the drug can be passed through breastmilk. It is not recommended for use in children under 16 years as safety and efficacy have not been established. In case of overdose, symptoms may include drowsiness, dizziness, anxiety, depression, etc., and as there is no specific antidote, appropriate medical treatment should be sought promptly. Finally, this medication should be stored out of the reach of children and it is safer to keep it in its original container to maintain its quality.
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly sealed container to prevent exposure to air and moisture. It is advisable to maintain a storage temperature between 1 and 30 degrees Celsius. Proper storage ensures the safety and effectiveness of the medication.
Gray oval film-coated tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowBrivaracetam 25mg
Tablet · Prescription medication
Hanin Pharmaceutical Co., Ltd.
Brivaracetam 1g
Solution · Prescription medication
UCB Korea Co., Ltd.
Brivaracetam 10mg
Tablet · Prescription medication
UCB Korea Co., Ltd.
Brivaracetam 25mg
Tablet · Prescription medication
UCB Korea Co., Ltd.
Brivaracetam 50mg
Tablet · Prescription medication
UCB Korea Co., Ltd.
Brivaracetam 100mg
Tablet · Prescription medication
UCB Korea Co., Ltd.

Brivaracetam 10mg
Tablet · Prescription medication
Daewoong Pharmaceutical Co., Ltd.

Brivaracetam 25mg
Tablet · Prescription medication
Daewoong Pharm. Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.